Drug Profile
HER2.taNK - ImmunityBio
Alternative Names: CAR-natural killer cell therapy - ImmunityBio; HER2.tank; HER2taNK; NK-92/5.28.z; taNK cells - NantKwest; Target-activated natural killer cells - ImmunityBioLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator NantKwest
- Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in Germany (Intracerebral, Injection)
- 13 Jan 2022 HER2.taNK is still in phase Ib trials for Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Germany (Intracerebral, Injection) (ImmunityBio pipeline, January 2022)
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio